We are live on ! Find out more
AMED

Amedisys

Delisted

AMED was delisted on the 14th of August, 2025.

304 hedge funds and large institutions have $3.02B invested in Amedisys in 2025 Q1 according to their latest regulatory filings, with 52 funds opening new positions, 113 increasing their positions, 84 reducing their positions, and 35 closing their positions.

New
Increased
Maintained
Reduced
Closed

49% more first-time investments, than exits

New positions opened: 52 | Existing positions closed: 35

35% more repeat investments, than reductions

Existing positions increased: 113 | Existing positions reduced: 84

10% more funds holding in top 10

Funds holding in top 10: 1011 (+1)

5% more funds holding

Funds holding: 290304 (+14)

1.41% more ownership

Funds ownership: 97.94%99.35% (+1.4%)

4% more capital invested

Capital invested by funds: $2.91B → $3.02B (+$108M)

97% less call options, than puts

Call options by funds: $6.96M | Put options by funds: $205M

Holders
304
Holders Change
+14
Holders Change %
+4.83%
% of All Funds
4.08%
Holding in Top 10
11
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+10%
% of All Funds
0.15%
New
52
Increased
113
Reduced
84
Closed
35
Calls
$6.96M
Puts
$205M
Net Calls
-$198M
Net Calls Change
+$89.8M
Name Holding Trade Value Shares
Change
Change in
Stake
Verition Fund Management
51
Verition Fund Management
Connecticut
$11.6M +$10M +108,607 +658%
PAMP
52
Polar Asset Management Partners
Ontario, Canada
$11.6M -$461K -5,000 -4%
MAM
53
Melqart Asset Management
United Kingdom
$11.3M +$11.2M +121,479 New
Squarepoint
54
Squarepoint
New York
$10.9M -$6.32M -68,562 -37%
OBAM
55
ODDO BHF Asset Management
France
$10.7M
JP Morgan Chase
56
JP Morgan Chase
New York
$9.58M +$1.38M +14,993 +17%
Goldman Sachs
57
Goldman Sachs
New York
$9.53M -$5.06M -54,865 -35%
Invesco
58
Invesco
Georgia
$8.83M +$412K +4,468 +5%
RhumbLine Advisers
59
RhumbLine Advisers
Massachusetts
$8.46M +$7.38K +80 +0.1%
QCM
60
Quantinno Capital Management
New York
$8.17M +$2.61M +28,334 +47%
Janus Henderson Group
61
Janus Henderson Group
United Kingdom
$7.33M -$1.26M -13,715 -15%
National Bank of Canada
62
National Bank of Canada
Quebec, Canada
$7.08M +$192K +2,087 +3%
Principal Financial Group
63
Principal Financial Group
Iowa
$6.98M +$30.8K +334 +0.4%
NC
64
Nicholas Company
Wisconsin
$6.88M +$3.23K +35 +0%
N
65
Nuveen
North Carolina
$6.64M +$1.21M +13,148 +22%
HF
66
HRT Financial
New York
$6.57M +$6.54M +70,972 New
Legal & General Group
67
Legal & General Group
United Kingdom
$6.43M +$101K +1,096 +2%
CC
68
Centiva Capital
New York
$6.36M -$3.83M -41,567 -38%
Jane Street
69
Jane Street
New York
$6.07M +$912K +9,892 +18%
CT
70
ClearAlpha Technologies
Connecticut
$5.91M +$384K +4,163 +7%
Swiss National Bank
71
Swiss National Bank
Switzerland
$5.88M -$83K -900 -1%
IG
72
ING Group
Netherlands
$5.74M
SG Americas Securities
73
SG Americas Securities
New York
$5.14M -$70.3K -763 -1%
Allianz Asset Management
74
Allianz Asset Management
Germany
$4.98M +$929K +10,074 +23%
PCM
75
Prelude Capital Management
New York
$4.95M +$2.87M +31,153 +140%

AMED Hedge Fund Activity: Q1 2025 in Review

304 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Amedisys (AMED) for Q1 2025, worth a combined $3.02B — up 3.7% from $2.91B a quarter earlier.

Buyers outnumbered sellers: 52 funds opened new AMED positions and 35 closed out — a net gain of 17 holders — while 113 added to existing stakes and 84 trimmed.

The largest buyer was Bank of America, adding an estimated $47.9M. The largest seller was Pacer Advisors, exiting entirely with an estimated $50.7M sold.

  • 304 institutional investors held Amedisys (AMED) as of Q1 2025, up from 290 in Q4 2024.
  • Funds reported $3.02B of Amedisys stock for Q1 2025, up 3.7% quarter-over-quarter.
  • 52 funds opened new Amedisys positions in Q1 2025 and 35 closed out, a net change of +17 holders.
  • The largest Amedisys buyer in Q1 2025 was Bank of America, an estimated $47.9M added.
  • The largest Amedisys seller in Q1 2025 was Pacer Advisors, an estimated $50.7M sold.

Based on aggregated 13F filings for Q1 2025.